{"entity":{"id":"idea-reg-early-apheresis-banking","kind":"idea","name":"Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy","aka":[],"tldr":"By the time patients need CAR-T their immune cells are often exhausted by earlier treatment. Storing healthy cells early would improve manufacturing success and cut the wait.","summary":"Manufacturing failures and poor CAR-T fitness are associated with prior lines of chemotherapy, bendamustine exposure and low lymphocyte counts. Collecting and cryopreserving autologous lymphocytes at diagnosis or first relapse for patients with a high probability of later needing CAR-T (high-risk large B-cell lymphoma, high-risk myeloma) would supply fitter starting material and remove apheresis scheduling from the critical path. The proposal is a prospective banking programme with defined eligibility, consent and storage funding, and a regulatory position on the use of banked material.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":[],"cancers":["dlbcl","multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":["paper-hernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Patients treated from banked early-collected cells have a manufacturing failure rate below 3% (versus 5-15% from late apheresis), a shorter referral-to-infusion interval by at least ten days, and higher CAR-T expansion and durable response rates.","rationale":"T-cell fitness is the strongest product-level predictor of CAR-T outcome, and it declines with each line of therapy; banking is routine for stem cells in myeloma and the storage cost is modest relative to the therapy.","test":"Prospective cohort banking cells in 300 newly diagnosed high-risk lymphoma patients, comparing manufacturing metrics and outcomes for those later needing CAR-T against contemporaneous patients apheresed at relapse.","maturity":"early-clinical","actor":"clinic","cost":"medium","horizonYears":4},"route":"/ideas/idea-reg-early-apheresis-banking/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"paper":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}